Sun Pharma secures nod for Ximino capsules

Company expects the extended-release capsules used for treating acne vulgaris will be available for patients during the fourth quarter of 2015

The US Food and Drug Administration has approved Sun Pharmaceutical’s supplemental new drug application for Ximino, extended-release capsules, strengthening its branded dermatology portfolio in the US market.

Sun announced on Wednesday it expected the extended-release capsules, used for treating acne vulgaris, would be available for patients during the December quarter.

Post its acquisition of Ranbaxy, the company has firmed up plans to make dermatology its biggest revenue segment and reports indicate it expects about 40 per cent of US sales to come from dermatology by FY18.

Last year the company also entered into a licencing agreement with Merck for a dermatology drug used for treatment of plaque psoriasis.